Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Document › Details

TVM Capital Life Science. (1/18/22). "Press Release: TVM Capital Life Science Promotes Dr. Sascha Berger and Dr. Alain Thibault to General Partner". Munich & Montréal.

	Organisation	TVM Capital Life Science
	Group	TVM (Group)
	Organisation 2	Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
	Today	Argenx SE (Euronext + Nasdaq: ARGX)
	Product	venture capital
	Product 2	LIFE SCIENCES
	Person	Berger, Sascha (TVM Capital 202201– promoted to General Partner joined 2016 before PricewaterhouseCoopers + BCG)

TVM Life Science (“TVM”), a leading International Life Sciences Venture Capital firm, today announces the formal promotion of Dr. Sascha Berger and Dr. Alain Thibault to General Partner.

Sascha has joined the TVM Capital Life Science team in 2016 as Principal and was promoted to Partner in 2020. Sascha has more than 15 years professional experience. He started his career as a management consultant at the Boston Consulting Group and later PricewaterhouseCoopers. He brings extensive experience in deal-making, life sciences venture capital, technology assessment and investment management with an academic background in chemistry and finance.

Alain joined the firm in 2020. He is a medical oncologist and an expert in first-in-man phase of oncology drug development. Prior to joining TVM, he held senior positions at Roche, Janssen, Regeneron and arGEN-X. His area of expertise includes chemotherapy, small molecule targeted therapy and biologics (monoclonal antibodies). His regulatory experience ranges from IND/IMPD-CTA write-up to IND/BLA submission and approval.

Dr. Hubert Birner, Managing Partner at TVM Capital Life Science commented, “Sascha will continue to play a pivotal role in sourcing and managing new investment opportunities for the firm, both for early stage and late-stage opportunities. Sascha already built a strong network into the transatlantic biotech and investor community. We are very pleased to announce Sascha’s promotion to General Partner today.”

Dr. Luc Marengere, Managing Partner at TVM Capital Life Science added, “Alain is a highly respected and accomplished medical oncologist with a strong track record in late pre-clinical/early clinical development in oncology where TVM is currently focusing our early-stage Project Focused Company investment strategy in partnership with Eli Lilly & Company. We are delighted to promote Alain to General Partner.”

Stefan Fischer, Managing Partner (Finance) at TVM Capital Life Science stated, “We wish both new partners continued success as they assume their new leadership responsibilities. This is based on their proven achievements, their strong expertise as well as their commitment to the values of our firm. They reflect the broad spectrum of our talent and know-how along the investment value chain and the valuable contribution to TVM’s portfolio.”

About TVM Capital Life Science

TVM Capital Life Science provides venture capital to international biopharmaceutical, medical technology, and diagnostic companies in North America and the EU. TVM follows a two-pronged strategy with a focus on early-stage and late-stage investments.

For more information please contact:

Stefan Fischer
Managing Partner (Finance), TVM Capital Life Science
fischer@tvm- capital.com
+49 89 998 992 36

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for TVM (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)